EIF2D Knockout NCI-H1299 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal population derived from the NCI-H1299 non-small cell lung cancer (NSCLC) cell line, featuring targeted disruption of the EIF2D gene. This product provides a genetically heterogeneous pool of cells with loss-of-function mutations in EIF2D, enabling functional studies of this translation initiation factor without the confounding biases of clonal selection. The polyclonal format preserves the diversity of tumor cell responses and is particularly suited for dissecting stress-adaptive translation programs in cancer.
Derived from a lymph node metastasis of a lung adenocarcinoma, the NCI-H1299 host cell line is a well-established model for NSCLC. These cells are p53-deficient and harbor wild-type KRAS, making them particularly valuable for studying oncogenic signaling pathways, metastatic mechanisms, and acquired drug resistance independent of KRAS-driven transformation. Their epithelial morphology and stable growth characteristics support a wide range of biochemical and genetic analyses.
EIF2D encodes a translation initiation factor that binds the 40S ribosomal subunit and interacts with eIF3, eIF2, eIF5, and PABP to facilitate re-initiation and cap-independent translation. Its activity is regulated upstream by nutrient deprivation, hypoxia, and ER stress through eIF2?? phosphorylation mediated by GCN2 and PERK, leading to ATF4 induction. Downstream, EIF2D-dependent translation controls the expression of key oncogenes and stress-response genes, including MYC, BCL2, CCND1, ATF4, and XBP1. Thus, EIF2D operates at the intersection of the integrated stress response and mTOR signaling pathways, where its interplay with 4E-BP1 and S6K1 shapes the proteome under adverse conditions.
In the NCI-H1299 background, EIF2D knockout disrupts translation re-initiation and cap-independent initiation, leading to reduced synthesis of proteins with structured 5?? UTRs that are enriched in oncogenic and stress-responsive factors. This impairs stress adaptation and attenuates signaling through pathways essential for lung adenocarcinoma cell proliferation and survival. Consequently, this polyclonal knockout model is a powerful tool for elucidating how translational reprogramming supports tumor progression and for identifying vulnerabilities in stress-tolerant cancer cells.
This product enables rigorous investigation of translation control mechanisms in cancer. Researchers can employ polysome profiling and RT-qPCR to assess changes in the translation efficiency of EIF2D target mRNAs, while western blotting validates the expression of downstream effectors such as MYC, BCL2, and ATF4. Functional assays, including cell viability, colony formation, and migration assays under basal and stress conditions (e.g., tunicamycin-induced ER stress), reveal the impact of EIF2D loss on tumor cell behavior. Furthermore, bicistronic reporter assays allow direct measurement of cap-independent translation activity. These applications support drug target validation and studies of stress-response pathways. For further information, please contact Ascent Research.
